The following table shows the changes made to the CSHCN Services Program Provider Manual through September 2018. The changes are listed in reverse chronological order (newest first).
|
December 2018 CSHCN Release Notes |
|
|
Chapter |
Related Articles and Notes |
|
Added form names to the listed drugs and products in subsection 3.1.1, “Prescription Drug Benefits.” |
|
|
Added and removed language throughout the chapter. |
|
|
Added TAC rule on sedation and anesthesia to section 14.1, “Enrollment.” |
|
|
Updated “DADS” reference with appropriate agency name in section 23.1, “Enrollment.” |
|
|
Removed the program name Health and Human Services Commission Texas Medicaid CHIP from the last statement in section 26.3.3, “Claims Information.” |
|
|
Removed DARS program in sections 31.2.6, “Audiometry/Hearing Services,” and 31.2.35, “Sign Language Interpreting Services,” and replaced with HHSC, as this agency is no longer referred to as DARS. Revised statement in section 31.2.24.15, “Respiratory Syncytial Virus (RSV) Prophylaxis,” by removing Health and Human Services Commission and adding statement about prior authorization form submissions for RSV. Update to ‘First Quarter 2018 HCPCS Updates for the CSHCN Services Program’ Quantity Limitation to Change for Botulinum Toxin Type A Procedure Code J0586 Revised statement in section 31.2.25.11, “Growth Hormone.” Removed Health and Human Services Commission Medicaid/CHIP, added prior authorization form name for Growth Hormone Products and updated link to Vendor Drug website; section 31.2.25.11.1, “Prior Authorization Requirements,” removed Texas Medicaid VDP and added prior authorization form name for Growth Hormone Products. |
|
|
Removed DADS program and replaced with HHSC to be consistent with provider enrollment requirements in section 33.1, “Enrollment.” |
|
|
Updated “DARS” reference with appropriate agency name in section 36.2, “Benefits, Limitations, and Authorization Requirements.” |
|
|
Updated “DARS” references with appropriate agency name. |
|
|
Removed “DARS” reference from section A.1, “Acronym Dictionary.” |
|
|
November 2018 CSHCN Release Notes |
|
|
Chapter |
Related Articles and Notes |
|
Updated language for emergency inpatient hospital admissions in section 4.3, “Prior Authorizations.” |
|
|
2018 ICD-10 Special Bulletin, No. 14 |
|
|
2018 ICD-10 Special Bulletin, No. 14 |
|
|
2018 ICD-10 Special Bulletin, No. 14 Hearing Services Benefits to Change Effective November 1, 2018 for the CSHCN Services Program |
|
|
2018 ICD-10 Special Bulletin, No. 14 |
|
|
2018 ICD-10 Special Bulletin, No. 14 |
|
|
2018 ICD-10 Special Bulletin, No. 14 |
|
|
2018 ICD-10 Special Bulletin, No. 14 |
|
|
October 2018 CSHCN Release Notes |
|
|
Chapter |
Related Articles and Notes |
|
Updated language to add “International classification of Disease” to section 1.2, “About the Provider Manual.” |
|
|
Removed diagnosis code descriptions in section 11.2.1.2, “Manual and Automated Blood Pressure Devices.” Removed procedure code descriptions in section 11.2.2.4, “Blood Pressure Device Components Repair or Replacement.” |
|
|
Removed diagnosis code descriptions in sections 15.2.1, “Glucose Monitor and Supplies,” and 15.2.1.1, “Non Diabetic Diagnosis Codes.” |
|
|
Removed diagnosis code descriptions in section 16.2.9, “Positron Emission Tomography (PET).” |
|
|
Removed diagnosis code descriptions in section Appendix A, “Diagnosis Codes for Diapers, Briefs, Pull-Ups, and Liners.” |
|
|
Revised CSHCN Services Program Prior Authorization Request for Inpatient Hospital Admission-For Use by Facilities Only Form Instructions, Effective October 1, 2018 Neonatal Level of Care Designation Required for Hospital Providers Rendering Neonatal Inpatient Services Removed diagnosis code descriptions in section 24.4.1.1, “Blood Factor Products.” |
|
|
Removed diagnosis code descriptions in section 25.2.5.2, “Cytogenetics Testing.” |
|
|
Removed procedure code description in section 26.4.4, “Reimbursement.” |
|
|
Global Update - removed the diagnosis description column from the tables of sections 27.2.1, “Dorsal Column Neurostimulation (DCN),” 27.2.2, “Intracranial Neurostimulation (ICN),” and 27.2.4, “Percutaneous Electrical Nerve Stimulation (PENS).” |
|
|
Removed diagnosis code descriptions in section 29.2.7.1, “Treatment for Alzheimer’s and Dementia.” |
|
|
Global Update - removed the diagnosis description column from the tables. Also removed diagnosis descriptions listed within statements. The following sections were updated: 31.2.2, “Aerosol Treatments/Inhalation Therapy,” 31.2.9, “Blood Factor Products,” 31.2.11, “Casting,” 31.2.17, “Echoencephalography,” 31.2.17.1, “Ambulatory Electroencephalogram,” 31.2.18.8, “Preventive Care Services,” 31.2.19.2, “Electromyography and Nerve Conduction Studies,” 31.2.20, “Extracorporeal Shock Wave Lithotripsy (ESWL),” 31.2.24.6, “Immunizations During an Office Visit,” 31.2.24.9, “Vaccine and Toxoid Procedure Codes,” 31.2.24.12, “Botulinum Antitoxin,” 31.2.25.3, “Injection Procedure Codes,” 31.2.25.6, “Bevacizumab,” 31.2.25.7, “Botulinum Toxin (Type A and Type B),” 31.2.25.10, “Erythropoietin Alfa (EPO) and Darbepoetin,” 31.2.36, “Skin Therapy,” 31.2.37.1, “Polysomnography,” 31.2.37.2, “Multiple Sleep Latency Test,” 31.2.37.3, “Pediatric Pneumogram,” 31.2.37.4, “Home Sleep Study Test,” 31.2.39.8, “Rhizotomy,” and 31.2.40, “Therapeutic Apheresis.” |
|
|
Removed diagnosis code descriptions in section 34.2.9, “Strontium-89.” |
|
|
Update to TMPPM and CSHCN Services Program Provider Manual for Texas Medicaid Wellness Program |
|
|
Removed diagnosis code descriptions in sections 40.2.1.4, “Contact Lenses,” and 40.2.3.3, “Corneal Topography.” |
|
|
September 2018 CSHCN Release Notes |
|
|
Handbook |
Related Articles and Notes |
|
Provider Practice Location Requirements for Moderate and High Risk Providers; PEP Enhancement for Facilities that Require Licensure, Effective August 24, 2018 |
|
|
Providers are Required to Fax Client Prior Authorization Requests Separately |
|